Quadrivalent Influenza Vaccine (QIV)
Seasonal Influenza Prevention
Key Facts
About Hualan Biological Engineering
Hualan Biological Engineering's mission is to safeguard public health through the research, development, and large-scale manufacturing of high-quality vaccines and plasma-based therapeutics. The company has achieved a leading market share in China's influenza vaccine segment and built a formidable, asset-heavy business model anchored by its extensive plasma station network and established manufacturing platforms. Its strategy focuses on defending its core franchises while strategically investing in next-generation vaccine technologies, including cell culture-based production and conjugate vaccines, to drive future growth and enhance pandemic preparedness.
View full company profileAbout Sinovac Biotech
Sinovac Biotech's mission is to supply vaccines to eliminate human infectious diseases worldwide. Its key achievement was the development and global distribution of CoronaVac, one of the most widely administered COVID-19 vaccines, which solidified its international standing and showcased its integrated manufacturing model. The company's strategy is anchored in its core inactivated vaccine technology platform, with a focus on expanding its pipeline for both endemic and pandemic threats while pursuing commercial partnerships in emerging markets. Financially, it faces the challenge of transitioning from peak pandemic revenue to a sustainable portfolio-driven growth model.
View full company profileTherapeutic Areas
Other Seasonal Influenza Prevention Drugs
| Drug | Company | Phase |
|---|---|---|
| Seasonal Influenza Vaccines | CSL Seqirus | Approved/Commercial |
| Influenza mRNA Vaccine | Pfizer | Phase 3 |
| Cell Culture-Based Quadrivalent Influenza Vaccine | Hualan Biological Engineering | Phase III |
| Trivalent Influenza Vaccine (TIV) | Hualan Biological Engineering | Marketed |